PPP2CA Is a Novel Therapeutic Target in Neuroblastoma Cells That Can Be Activated by the SET Inhibitor OP449.

Galiger C, Dahlhaus M, Vitek MP, Debatin KM, Beltinger C

Open source

DOI
10.3389/fonc.2022.744984
Published
2022
Container
Frontiers in oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2022.744984,
  title = {PPP2CA Is a Novel Therapeutic Target in Neuroblastoma Cells That Can Be Activated by the SET Inhibitor OP449.},
  author = {Galiger C and Dahlhaus M and Vitek MP and Debatin KM and Beltinger C},
  year = {2022},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2022.744984},
  url = {https://doi.org/10.3389/fonc.2022.744984}
}

RIS

TY  - JOUR
TI  - PPP2CA Is a Novel Therapeutic Target in Neuroblastoma Cells That Can Be Activated by the SET Inhibitor OP449.
AU  - Galiger C
AU  - Dahlhaus M
AU  - Vitek MP
AU  - Debatin KM
AU  - Beltinger C
PY  - 2022
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2022.744984
UR  - https://doi.org/10.3389/fonc.2022.744984
ER  - 

APA

C, G., M, D., MP, V., KM, D., & C, B. (2022). PPP2CA Is a Novel Therapeutic Target in Neuroblastoma Cells That Can Be Activated by the SET Inhibitor OP449.. Frontiers in oncology. https://doi.org/10.3389/fonc.2022.744984

Source records